Abbasi Abdul Muqtadir, Shaikh Mohammad Usman, Ali Natasha, Khan Maria, Soomar Salman Muhammad
Department of Oncology, Aga Khan University Karachi Pakistan.
Department of Pathology & Laboratory Medicine, Aga Khan University Karachi Pakistan.
Leuk Res Rep. 2022 Feb 16;17:100295. doi: 10.1016/j.lrr.2022.100295. eCollection 2022.
Eltrombopag has been used in ITP and found its use in AA armamentarium recently. We retrospectively analyzed 61 patients at a tertiary care center in Pakistan from January 2015 to January 2021. They included patients with severe AA who were refractory to at least one course of immunosuppressive therapy and persistent/chronic ITP who have received at least one previous treatment for ITP. Responses to Eltrombopag in our population were comparable to real-world experiences while tolerable hepatotoxicity and GI issues were notable. We found Eltrombopag to be a safe and efficacious agent for treating patients with ITP and AA.
艾曲泊帕已用于治疗免疫性血小板减少症（ITP），最近还被纳入再生障碍性贫血（AA）的治疗药物中。我们对巴基斯坦一家三级医疗中心2015年1月至2021年1月期间的61例患者进行了回顾性分析。这些患者包括对至少一个疗程免疫抑制治疗无效的重型AA患者，以及既往至少接受过一次ITP治疗的持续性/慢性ITP患者。在我们的研究人群中，艾曲泊帕的疗效与实际临床经验相当，同时值得注意的是，其肝毒性和胃肠道问题在可耐受范围内。我们发现艾曲泊帕是一种治疗ITP和AA患者安全有效的药物。
